

(English version)

**Question for written answer E-001673/26
to the Commission
Piotr Müller (ECR)
(23 April 2026)**

Subject: Strengthening the EU's manufacturing capacity in critical medicines and reducing dependence on supply chains from third countries

Given the increasing risk of shortages of critical medicines in Member States, including Poland, and the EU's persistently high dependence on the supply of active substances and finished medicinal products from third countries, in particular from Asia, I would like to ask:

1. Is the Commission considering introducing mandatory minimum production levels for selected medicines in the EU?
2. Is the Commission analysing the impact of current environmental and energy regulations on the competitiveness of medicine production in Europe?
3. Is the Commission considering introducing solutions that reward European production of critical medicines in public procurement in order to make health systems more resilient to geopolitical and logistical crises?

Submitted: 23.4.2026

**Answer given by Mr Várhelyi on behalf of the European Commission
(3 July 2026)**

Whilst no mandatory minimum production levels for selected medicines exist in the EU, for medicines identified as dependent and vulnerable to supply chain disruptions the Critical Medicines Act⁽¹⁾ (on which political agreement was reached on 12 May 2026) introduces measures to favour EU-based manufacturing in public procurement procedures.

The Critical Medicines Act also includes concrete steps to support European production of critical medicines in public procurement. The measures aim to boost supply chain diversification and resilience.

Contracting authorities will be able to incentivise their manufacturing in the EU, for example by rewarding suppliers proportionally to the share of medicinal products and their active pharmaceutical substances manufactured in the EU.

Before adopting any new legislation, including legislation in the fields of environment and energy, the Commission analyses the possible socioeconomic impacts, in line with the principles of Better Regulation.

⁽¹⁾ Proposal for a regulation of the European Parliament and of the Council laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795, COM/2025/102 final.